GOALS AND BACKGROUND: The objective is to develop a patient-based Harvey Bradshaw Index (P-HBI) of Crohn's Disease (CD) activity and to compare it with the clinician-based HBI of CD activity in CD outpatients. STUDY: Consecutive patients with CD randomly completed the P-HBI either before or after the consultation. The gastroenterologist assessed patient's CD activity on the same day. Overall agreement between HBI and P-HBI was calculated with Spearman's ρ and Mann-Whitney U test. Agreement regarding active disease versus remission and agreement at item level was calculated by percent agreement and Cohen's κ. RESULTS:One hundred eighty-one (response rate 88.3%) CD patients participated. P-HBI and HBI showed a large correlation (rs=0.82). The medians (interquartile range) of the total HBI (2; 0 to 4) and P-HBI (4; 1 to 7) were statistically significantly different (z=-8.411; P<0.001). Fortunately, in 82.6% of the cases this difference between clinicians and patients was not clinically significant (<3.2). The percentage agreement between clinician and patient, judging CD as active or as in remission, was 77%, rs=0.56, κ=0.52, indicating a moderate agreement. P-HBI and HBI on frequent extraintestinal manifestations in CD varied from less than chance (κ=-0.02) to a perfect agreement (κ=1). Patients tended to report more symptoms while completing the patient-based questionnaire compared to what they reported to the clinician during consultation. CONCLUSIONS: The P-HBI is the first step in developing a potential promising tool given its adequate agreement with the original HBI and its feasibility, especially in patients with low scores. Future research is necessary to develop a validated patient-based version studied in several patient populations.
RCT Entities:
GOALS AND BACKGROUND: The objective is to develop a patient-based Harvey Bradshaw Index (P-HBI) of Crohn's Disease (CD) activity and to compare it with the clinician-based HBI of CD activity in CD outpatients. STUDY: Consecutive patients with CD randomly completed the P-HBI either before or after the consultation. The gastroenterologist assessed patient's CD activity on the same day. Overall agreement between HBI and P-HBI was calculated with Spearman's ρ and Mann-Whitney U test. Agreement regarding active disease versus remission and agreement at item level was calculated by percent agreement and Cohen's κ. RESULTS: One hundred eighty-one (response rate 88.3%) CD patients participated. P-HBI and HBI showed a large correlation (rs=0.82). The medians (interquartile range) of the total HBI (2; 0 to 4) and P-HBI (4; 1 to 7) were statistically significantly different (z=-8.411; P<0.001). Fortunately, in 82.6% of the cases this difference between clinicians and patients was not clinically significant (<3.2). The percentage agreement between clinician and patient, judging CD as active or as in remission, was 77%, rs=0.56, κ=0.52, indicating a moderate agreement. P-HBI and HBI on frequent extraintestinal manifestations in CD varied from less than chance (κ=-0.02) to a perfect agreement (κ=1). Patients tended to report more symptoms while completing the patient-based questionnaire compared to what they reported to the clinician during consultation. CONCLUSIONS: The P-HBI is the first step in developing a potential promising tool given its adequate agreement with the original HBI and its feasibility, especially in patients with low scores. Future research is necessary to develop a validated patient-based version studied in several patient populations.
Authors: Orly Sarid; Vered Slonim-Nevo; Doron Schwartz; Michael Friger; Ruslan Sergienko; Avihu Pereg; Hillel Vardi; Elena Chernin; Terri Singer; Dan Greenberg; Shmuel Odes Journal: Int J Behav Med Date: 2018-06
Authors: Tiffany H Taft; Alyse Bedell; Meredith R Craven; Livia Guadagnoli; Sarah Quinton; Stephen B Hanauer Journal: Inflamm Bowel Dis Date: 2019-08-20 Impact factor: 5.325
Authors: Ersilia M DeFilippis; Saniya Tabani; Ryan U Warren; Paul J Christos; Brian P Bosworth; Ellen J Scherl Journal: Dig Dis Sci Date: 2015-08-09 Impact factor: 3.199
Authors: Mike van der Have; Bas Oldenburg; Ad A Kaptein; Jeroen M Jansen; Robert C H Scheffer; Bas A van Tuyl; Andrea E van der Meulen-de Jong; Marieke Pierik; Peter D Siersema; Martijn G H van Oijen; Herma H Fidder Journal: J Crohns Colitis Date: 2016-01-06 Impact factor: 9.071
Authors: O Sarid; V Slonim-Nevo; A Pereg; M Friger; R Sergienko; D Schwartz; D Greenberg; I Shahar; E Chernin; H Vardi; L Eidelman; A Segal; G Ben-Yakov; N Gaspar; D Munteanu; A Rozental; A Mushkalo; V Dizengof; N Abu-Freha; A Fich; S Odes Journal: PLoS One Date: 2017-02-28 Impact factor: 3.240